HEMOBIOTECH, INC.·4

Dec 17, 4:12 PM ET

DRAGOO ROBERT E. 4

4 · HEMOBIOTECH, INC. · Filed Dec 17, 2010

Insider Transaction Report

Form 4
Period: 2010-12-13
Transactions
  • Award

    Options to Purchase Common Stock

    2009-09-25+7,00036,000 total
    Exercise: $0.27From: 2009-09-25Exp: 2019-09-25Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2009-12-31+12,00078,000 total
    Exercise: $0.31From: 2009-12-31Exp: 2019-12-31Common Stock (12,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-09-24+7,000126,000 total
    Exercise: $0.30From: 2010-09-24Exp: 2020-09-24Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2009-10-31+23,00059,000 total
    Exercise: $0.25From: 2009-10-31Exp: 2019-10-31Common Stock (23,000 underlying)
  • Award

    Options to Purchase Common Stock

    2009-12-24+7,00066,000 total
    Exercise: $0.50From: 2009-12-24Exp: 2019-12-24Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-06-25+7,000104,000 total
    Exercise: $0.40From: 2010-06-25Exp: 2020-06-25Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-09-24+19,000145,000 total
    Exercise: $0.30From: 2010-09-24Exp: 2020-09-24Common Stock (19,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-03-26+7,00085,000 total
    Exercise: $0.51From: 2010-03-26Exp: 2020-03-26Common Stock (7,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-03-26+12,00097,000 total
    Exercise: $0.51From: 2010-03-26Exp: 2020-03-26Common Stock (12,000 underlying)
  • Award

    Options to Purchase Common Stock

    2010-06-25+15,00011,900 total
    Exercise: $0.40From: 2010-06-25Exp: 2020-06-25Common Stock (15,000 underlying)
Footnotes (12)
  • [F1]From October 31, 2009 through September 30, 2010, the board of directors received additional options in lieu of their quarterly compensation. These options are immediately vested and exercisable upon issuance.
  • [F10]The Options to Purchase Common Stock were granted on June 25, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F11]The Options to Purchase Common Stock were granted on September 24, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F12]The Options to Purchase Common Stock were granted on September 24, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F2]On November 18, 2010, the board of directors of HemoBioTech, Inc. agreed to reprice all options to $.25.
  • [F3]The Options to Purchase Common Stock were granted on September 25, 2009. All Options are immediately vested and exercisable upon issuance.
  • [F4]The Options to Purchase Common Stock were granted on October 31, 2009. All Options are immediately vested and exercisable upon issuance.
  • [F5]The Options to Purchase Common Stock were granted on December 24, 2009. All Options are immediately vested and exercisable upon issuance.
  • [F6]The Options to Purchase Common Stock were granted on December 31, 2009. All Options are immediately vested and exercisable upon issuance.
  • [F7]The Options to Purchase Common Stock were granted on March 26, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F8]The Options to Purchase Common Stock were granted on March 26, 2010. All Options are immediately vested and exercisable upon issuance.
  • [F9]The Options to Purchase Common Stock were granted on June 25, 2010. All Options are immediately vested and exercisable upon issuance.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4